Precise, pragmatic and inclusive: the modern era of oncology clinical trials

Affiliations

¹ Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
² Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. sarah.goldberg@yale.edu.

Comment

Michael J Grant et al. Nat Med. 2023 Aug.

. 2023 Aug;29(8):1908-1909.

doi: 10.1038/s41591-023-02466-6.

¹ Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
² Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. sarah.goldberg@yale.edu.

No abstract available

Comment on

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, Zhou Z, Xu CR, Zheng MY, Li YS, Wang Z, Bai XY, Li AN, Sun YL, Huang J, Lin JX, Ke EE, Xu BF, Lu C, Du Y, Chen Y, Ma R, Wang BH, Cang SD, Wang BC, Chen HJ, Yang JJ, Li Y, Zhou Q, Wu YL. Liu SM, et al. Nat Med. 2023 Aug;29(8):2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488286 Clinical Trial.

1. Riudavets, M., Sullivan, I., Abdayem, P. & Planchard, D. ESMO Open 6, 100260 (2021). - DOI - PubMed - PMC
1. Li, B. T. et al. N. Engl. J. Med. 386, 241–251 (2022). - DOI - PubMed
1. Subbiah, V. Nat. Med. 29, 49–58 (2023). - DOI - PubMed
1. Liu, S. Y. M. T. H. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02461-x (2023). - DOI - PubMed - PMC
1. Redman, M. W. et al. Lancet Oncol. 21, 1589–1601 (2020). - DOI - PubMed - PMC